We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
- Authors
Cooksley, T; Weaver, J; McNamara, M; Lorigan, P
- Abstract
This article discusses the occurrence of immune checkpoint inhibitor-related myasthenia gravis, myocarditis, and myositis, which can occur early after the initiation of therapy and have a high mortality rate. The clinical course of immune checkpoint inhibitor-mediated myasthenia gravis is more aggressive than its de novo counterparts, and management strategies need to be adjusted accordingly. The article presents a case study of a 66-year-old woman with metastatic distal bile duct cholangiocarcinoma who developed symptoms of nausea and fatigue after receiving Pembrolizumab. The patient experienced bilateral ptosis and elevated Troponin levels, leading to the diagnosis of immune-mediated myasthenia gravis, myocarditis, and myositis. The article suggests that early recognition and treatment of these toxicities may improve outcomes, and further research is needed to explore monitoring methods for cardiac biomarkers.
- Subjects
IMMUNE checkpoint proteins; MYOSITIS; MYASTHENIA gravis; MYOCARDITIS; CARDIAC magnetic resonance imaging
- Publication
QJM: An International Journal of Medicine, 2024, Vol 117, Issue 5, p373
- ISSN
1460-2725
- Publication type
Article
- DOI
10.1093/qjmed/hcae006